Based on RRR associated with an increase in Hb ≥1 g/dL (Table 3) with voxelotor treatment, the incidences of stroke, PH, CKD, and death are projected to decrease by 19.8%, 24.5%, 25.1%, and 39.4%, respectively, over the next 20 years with the availability of voxelotor (Fig 5). This evidence concerns the gene GSTM1 and chronic kidney disease.